⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked sharesUnlock shares

KRMD stock touches 52-week high at $4.20 amid robust growth

Published 12/12/2024, 19:36
KRMD
-

In a remarkable display of resilience and growth, Repro Med Systems , Inc. (NASDAQ:KRMD) stock has soared to a 52-week high, reaching a price level of $4.20. With a market capitalization of $191 million and an impressive revenue growth of 11.6% in the last twelve months, the company has caught investors' attention. InvestingPro analysis reveals the company maintains a healthy current ratio of 2.99, indicating strong liquidity management. This significant milestone underscores the company's strong performance over the past year, which is further highlighted by an impressive 1-year change of 73.33%. Investors have shown increased confidence in the medical device company's strategy and market position, propelling the stock to new heights and reflecting optimism in its future prospects. The 52-week high serves as a testament to Repro Med Systems' robust financial health, earning a "GOOD" overall rating from InvestingPro, and its potential for continued success in the competitive healthcare sector. For deeper insights into KRMD's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, KORU Medical (TASE:PMCN) Systems reported robust growth in its Q3 earnings call. The company announced a 17% year-over-year revenue increase to $8.2 million, highlighting growth in both domestic and international markets. The surge in Novel Therapies revenues, which rose by 276% to $600,000, and an improved gross margin of 63.4% were among the key developments. The company also raised its full-year revenue guidance, indicating optimism for continued growth.

In other developments, KORU provided an updated timeline for its regulatory submissions, including a 510(k) for a next-generation device expected in mid-2025. The company is focusing on expanding its core SCIG business and entering new markets, with six drug launches expected by 2026. Lastly, KORU plans to achieve cash flow breakeven in Q4 and operational cash flow positivity in 2025. These are among the recent developments for KORU Medical Systems.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.